Monod Bio, a spinout from David Baker’s lab, presented its AI platform for designing compact antibody mimics called NovoBodies—single‑chain, 27 kDa proteins engineered to reproduce antibody binding while offering enhanced biophysical properties and customizable residues for conjugation. The company said NovoBodies can be derived computationally from existing antibodies, engineered for high affinity and modified to control lysine and cysteine content—key sites for payload attachment. The platform targets research reagents and therapeutic applications where size, stability and modular chemistry are advantages.